Get started
Author

Ascensión López-Dı́az de Cerio

Observed names: A L de Cerio, A Lopez-Diaz De Cerio, A Lopez‐Diaz de Cerio, A López-Díaz de Cerio, A. Diaz De Cerio, A. L. de Cerio, A. L.-D. de Cerio, A. L.‐D. De Cerio, A. Lopez-Diaz de Cerio, A. Lòpez-Dìaz de Cerio, A. López-Diaz de Cerio, A. López-Díaz de Cerio, A. de Cerio, A.Lopez-Diaz de Cerio, Ascension Lopez-Diaz de Cerio, Ascension Lopez-diaz De Cerio, Ascension López-Díaz de Cerio, Ascensión Lopez-Diaz de Cerio, Ascensión López-Díaz de Cerio, Ascensiòn Lòpez-Dìaz de Cerio, Ascensión L de Cerio, Ascensión Lopez-Diaz de Cerio, Ascensión Lopez-Díaz de Cerio, Ascensión Lopez‐Diaz de Cerio, Ascensión López-Diaz De Cerio, Ascensión López-Diaz de Cerio, Ascensión López-Díaz De Cerio, Ascensión López-Díaz de Cerio, Ascensión López-Díaz-de-Cerio, Ascensión López‐Diaz de Cerio, Ascensión López‐Díaz de Cerio, Ascensión de Cerio, Ascensión López-Díaz de Cerio, Lopez-Diaz de Cerio, A., Lopez-Diaz de Cerio, Ascension
Observed institutions: Universidad de Salamanca, Complejo Hospitalario de Navarra, Navarre Institute of Health Research, Centro de Investigación Biomédica en Red, Hospital Clínic de Barcelona, Clinica Universidad de Navarra, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Centro de Investigación Médica Aplicada, Universitat de Barcelona, Universidad de Sevilla, Universidad de Murcia, Universidad de Navarra
ORCID: 0000-0002-7837-135X
Observed ORCID: 0000-0002-7837-135X
OpenAlex ID: A5022553370
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
2019 · Kurt A. Schalper, Maria E. Rodriguez-Ruiz, et al. · Nature Medicine · 642
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-γ-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
2003 · Noelia Casares, Laura Arribillaga, et al. · The Journal of Immunology · 196
PDF
Rapid, high-yield production in plants of individualized idiotype vaccines for non-Hodgkin's lymphoma
2010 · M. Bendandi, S. Marillonnet, et al. · Annals of Oncology · 189
Targeting NK-cell checkpoints for cancer immunotherapy
2017 · Aura Muntasell, Maria C Ochoa, et al. · Current Opinion in Immunology · 182
Abnormal Priming of CD4 + T Cells by Dendritic Cells Expressing Hepatitis C Virus Core and E1 Proteins
2002 · Pablo Sarobe, Juan José Lasarte, et al. · Journal of Virology · 166
Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma
2006 · Susana Inogès, Mercedes Rodrìguez-Calvillo, et al. · JNCI Journal of the National Cancer Institute · 150
PDF
Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
2018 · M.E. Rodríguez-Ruiz, J.L. Perez-Gracia, et al. · Annals of Oncology · 145
IL‐10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis
2008 · Ivan Martinez‐Forero, Ricardo Garcia‐Munoz, et al. · European Journal of Immunology · 142
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
2017 · Susana Inogés, Sonia Tejada, et al. · Journal of Translational Medicine · 138
PDF
Human Follicular Lymphoma Cells Contain Oligomannose Glycans in the Antigen-binding Site of the B-cell Receptor
2006 · Catherine M. Radcliffe, James N. Arnold, et al. · Journal of Biological Chemistry · 134
PDF
CD28 Aptamers as Powerful Immune Response Modulators
2013 · Fernando Pastor, Mario M Soldevilla, et al. · Molecular Therapy — Nucleic Acids · 125
Imiquimod Enhances the Systemic Immunity Attained by Local Cryosurgery Destruction of Melanoma Lesions
2007 · Pedro Redondo, Julio del Olmo, et al. · Journal of Investigative Dermatology · 110
PDF
CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome
2022 · Paula Rodriguez-Marquez, Maria E. Calleja-Cervantes, et al. · Science Advances · 108
PDF
Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration
2019 · Barbara Willekens, Silvia Presas-Rodríguez, et al. · BMJ Open · 102
PDF
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
2023 · Aina Oliver-Caldés, Verónica González-Calle, et al. · The Lancet Oncology · 98
PDF
Immunization with a tumor-associated CTL epitope plus a tumor-related or unrelated Th1 helper peptide elicits protective CTL immunity
2001 · Noelia Casares, Juan José Lasarte, et al. · European Journal of Immunology · 84
PDF
2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia
2015 · Mario Martinez Soldevilla, Helena Villanueva, et al. · Biomaterials · 80
Clinical Safety and Immunogenicity of Tumor-Targeted, Plant-Made Id-KLH Conjugate Vaccines for Follicular Lymphoma
2015 · Daniel Tusé, Nora Ku, et al. · BioMed Research International · 70
PDF
Anti-idiotype antibodies in cancer treatment
2007 · A López-Díaz de Cerio, N Zabalegui, et al. · Oncogene · 62
Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation
2005 · Maurizio Bendandi, Mercedes Rodríguez-Calvillo, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 60
Different Doses of Adenoviral Vector Expressing IL-12 Enhance or Depress the Immune Response to a Coadministered Antigen: the Role of Nitric Oxide
1999 · Juan José Lasarte, Fernando José Corrales, et al. · The Journal of Immunology · 60
PDF
A randomized phase II clinical trial of dendritic cell vaccination following complete resection of colon cancer liver metastasis
2018 · Javier Rodriguez, Eduardo Castañón, et al. · Journal for ImmunoTherapy of Cancer · 56
PDF
Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)
2017 · Mario Martínez Soldevilla, Sandra Hervas, et al. · PLoS ONE · 42
PDF
Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies.
2004 · Natalia Zabalegui, Ascensión López-Díaz de Cerio, et al. · PubMed · 36
PDF
Potentiation of therapeutic immune responses against malignancies with monoclonal antibodies.
2003 · Oihana Murillo, Ainhoa Arina, et al. · PubMed · 35
PDF
Works count: 155
Citation count: 3,720
H-index: 27
I10-index: 47
Year
Topic
Type